prescription retatrutide Phase 3: 60% Achieved Surgical-Level Weight Loss Retatrutide vs. Tirzepatide: The New

This approach recognises that bariatric surgery itself influences GLP-1 physiologyprocedures such as gastric bypass typically increase endogenous GLP-1 levels, contributing to post-operative weight loss

Contact NHS 111 or your GP immediately if you have taken a double dose

Best results with consistent, daily use for 3-6 months

Compounded versions of semaglutide and tirzepatide are not FDA-approved, and their safety and effectiveness have not been approved by the FDA

GLP-1R agonists such as semaglutide, tirzepatide, and mazdutide not only promote insulin secretion, suppress appetite, and delay gastric emptying, thereby effectively reducing body weight, but also help improve lipid profiles and reduce the risk of cardiovascular diseases

Perioperative Early case reports called into question appropriate fasting times for pre-procedural and operative fasting due to retained gastric contents and risk of aspiration in patients taking GLP-1 medications and compounds [213,214]